Abstract Structural variants (SVs) are increasingly recognized as key drivers of tumorigenesis, yet current technologies struggle to detect and accurately characterize them due to resolution limitations and sequencing constraints. As a result, attempts to produce complete somatic SV truth sets often suffer due to the gaps in detection performance of the sequencing technology utilized, impacting the truth sets’ usefulness for benchmarking alternative technologies and/or SV callers. To this end, the National Institute of Standards Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 517.
Sanborn et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: